MedTrace Logo

Combined Distal Femoral Nerve Block for Pain Control After Knee Replacement

NCT07629388 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-06-05

No results posted yet for this study

Summary

The goal of this clinical trial is to see whether a combined distal femoral nerve block improves pain relief after total knee replacement in adults having planned surgery. The main questions it aims to answer are:

* Does the combined distal femoral nerve block reduce the amount of opioid needed in the post-anesthesia recovery room?
* Does it preserve quadriceps muscle strength while improving postoperative pain control?

Researchers will compare the combined distal femoral nerve block to a saphenous nerve block alone to see if the combined block provides better analgesia without reducing leg strength.

Participants will:

* Receive either the combined distal femoral nerve block or the saphenous nerve block alone before surgery.
* Also receive standard multimodal pain management, including anesthesia, surgical site infiltration, and postoperative pain medications.
* Be assessed for pain, opioid use, nausea and vomiting, quadriceps strength, time to first standing, hospital stay length, and patient satisfaction from surgery until discharge.

Conditions

  • Pain After Total Knee Arthroplasty
  • Pain Management

Interventions

PROCEDURE

Combined distal femoral nerve block

Ultrasound-guided block targeting the saphenous nerve, vastus medialis nerve, and anterior femoral cutaneous nerves, using ropivacaine 2 mg/mL, 40 mL total, with clonidine 30 micrograms perineural and dexamethasone 8 mg IV.

PROCEDURE

Saphenous nerve block alone

Ultrasound-guided saphenous nerve block at the adductor canal, using ropivacaine 2 mg/mL, 20 mL total, with clonidine 30 micrograms perineural and dexamethasone 8 mg IV.

PROCEDURE

Standard perioperative care in both groups

General anesthesia, surgical site infiltration, and multimodal analgesia with paracetamol, nefopam, and ketoprofen.

Sponsors & Collaborators

  • GCS Ramsay Santé pour l'Enseignement et la Recherche

    lead OTHER

Principal Investigators

  • Antoine Sanchez, MD · Hôpital privé Dijon Bourgogne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-25
Primary Completion
2027-05-25
Completion
2027-05-25

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07629388 on ClinicalTrials.gov